Validation of an immunoassay to selectively quantify the naked antibody of a new Antibody Drug Conjugate - SAR566658 - for pharmacokinetic interpretation improvement

Journal of Immunological Methods

Volumn 396, Issue 1-2, 2013, Pages 140-146

  Pascual, Marie Helene ^a   Verdier, Patrick ^a   Malette, Patricia ^a   Mnich, Jonathan ^a   Ozoux, Marie Laure ^a  

^a SANOFI   (France)

Author keywords

Antibody drug conjugate; Immunobeads; Immunopurification; Naked antibody; Pharmacokinetics; Specificity

Indexed keywords

ANTIBODY CONJUGATE; SAR 566658; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOASSAY; IN VITRO STUDY; LIMIT OF QUANTITATION; MOLECULE; PLASMA HALF LIFE; PRIORITY JOURNAL; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

%DIFF; ΜG/ML; ADA; ADC; ANTI-DRUG ANTIBODIES; ANTIBODY DRUG CONJUGATE; COEFFICIENT OF VARIATION; CV%; DIFFERENCE FROM NOMINAL CONCENTRATIONS; DM4; EIA; EMA; ENZYME IMMUNOASSAY; EUROPEAN MEDICINES AGENCY; FDA; FOOD AND DRUG ADMINISTRATION; HPAC; HUMAN PANCREATIC ADENOCARCINOMA CELLS; IMMUNOBEADS; IMMUNOPURIFICATION; LC-MS/MS; LIHE; LIQUID CHROMATOGRAPHY COUPLE WITH TANDEM MASS SPECTROMETRY; LITHIUM HEPARINATE; LLOQ; LOWER LIMIT OF QUANTITATION; MAYTANSIN; MICROGRAM PER MILLILITER; NAKED ANTIBODY; NANOGRAM PER MILLILITER; NG/ML; PBST; PHARMACOKINETICS; PHOSPHATE BUFFER SALINE - TWEEN; POOR REPLICATE; PR; SPECIFICITY; ULOQ; UPPER LIMIT OF QUANTITATION; VALIDATION SAMPLES; VS;

ANTIBODIES; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOASSAY; MALE; PHARMACEUTICAL PREPARATIONS;

EID: 84884352672     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.06.012     Document Type: Article

References (17)

1. Carrigan C., Zuany-Amorim C., Mayo M.F., Tavares D.J., Lutz R.J., Kellogg A.E., Blanc V., Vrignaud P., Bissery M.C., Payne G. Preclinical Evaluation of SAR566658 (huDS6-DM4) in Mice Bearing Human Tumor Xenografts of Breast, Ovarian, Lung, Cervical and Pancreatic Cancer. Geneva Abstract #ENA-0184, 6(12), Poster 525 2008.
2. Chudasama V.L., Schaedeli S.F., Harrold J.M., Tibbitts J., Girish S.R., Gupta M., et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2012, 92(4):520.
3. Ducry L., Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem. 2010, 21:5.
4. Erickson H.K., Widdison W.C., Mayo M.F., Whiteman K., Audette C., Wilhelm S.D., Singh R. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug. Chem. 2010, 21:84.
5. Erickson H.K., Lewis Phillips G.D., Leipold D.D., et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol. Cancer Ther. 2012, 11(5):1133.
6. Girish S., Gupta M., Wang B., Lu D., Krop I.E., Vogel C.L., Burris Iii H.A., Lorusso P.M., Yi J.H., Saad O., Tong B., Chu Y.W., Holden S., Joshi A. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2- positive cancer. Cancer Chemother. Pharmacol. 2012, 69:1229.
7. Gorovits B., Alley S.C., Bilic S., Booth B., Kaur S., Oldfield P., et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 2013, 5(9):997.
8. Kellner C., Bleeker W.K., Lammerts van Bueren J.J., Staudinger M., Klausz K., Derer S., Glorius P., Muskulus Ade Goeij B.E.C.G., van de Winkel J.G.J., Parren P.W.H.I., Valerius T., Gramatzki M., Peipp M. Human kappa light chain targeted Pseudomonas exotoxin A - identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. J. Immunol. Methods 2011, 371:122.
9. Lapusan S., Vidriales M.B., Thomas X., de Botton S., Vekhoff A., Tang R., Dumontet C., Morariu-Zamfir R., Lambert J.M., Ozoux M.L., Poncelet P., San Miguel J.F., Legrand O., DeAngelo D.J., Giles F.J., Marie J.P. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest. New Drugs 2012, 30(3):1121.
10. Lin K., Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm. Res. 2012, 29:2354.
11. LoRusso P.M., Weiss D., Guardino E., Girish S., Sliwkowski M. Trastuzumab ematansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 2011, 17(20):6437.
12. Pascual M.H., Verdier P., Malette P., Ozoux M.L. Relevance of an Immunoassay That Selectively Quantifies the Naked Antibdy for the Pharmacokinetic Interpretation of an Antibody Drug Conjugate. Barcelona European Bioanalysis Forum, Poster 2012.
13. Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30(7):631.
14. Stephan J.P., Chan P., Lee C., Nelson C., Elliott J.M., Bechtel C., Raab H., Xie D., Akutagawa J., Baudys J., Saad O., Prabhu S., Wong W.L.T., Vandlen R., Jacobson F., Ebens A. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem. 2008, 19:1673.
15. Stephan J.P., Kozak K.R., Wong W.L.T. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 2011, 3(6):677.
16. Teicher B.A., Chari R.V.J. Antibody conjugate therapeutics challenges and potential. Clin. Cancer Res. 2011, 17(20):6389.
17. Wakankar A., Chen Y., Gokarn Y., Jacobson F.S. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011, 3(2):161.